Seasonal influenza vaccination and antiviral use in EU/EEA Member States
Overview of vaccine recommendations for 2017–2018 and vaccination coverage rates for 2015–2016 and 2016–2017 influenza seasons.
Influenza vaccination coverage rates insufficient across EU Member States
None of the European Union (EU) Member States could demonstrate that they reach the EU target of 75% influenza vaccination coverage for vulnerable groups, according to a new report from the European Centre for Disease Prevention and Control (ECDC).
A systematic review on models of care effectiveness and barriers to Hepatitis C treatment in prison settings in the EU/EEA
Vroling, H., Oordt-Speets, A.M., Madeddu, G., Babudieri, S., Monarca, R., O'Moore, E., Vonk Noordegraaf-Schouten, M., Wolff, H., Montanari, M., Hedrich, D., Tavoschi, L.
Table of contributions for the expert opinion on neuraminidase inhibitors for the prevention and treatment of influenza
The 'Table of contributions' contains all comments received through a public consultation on this topic and lists ECDC’s responses to those comments.
Expert opinion on neuraminidase inhibitors for the prevention and treatment of influenza - review of recent systematic reviews and meta-analyses
This ECDC expert opinion confirms earlier assessments by ECDC and national authorities that there is no significant new evidence to support any changes to the approved indications and recommended use of neuraminidase inhibitors (NAIs) in EU/EEA Member States.
Expert panel reviews neuraminidase inhibitors for the prevention and treatment of influenza
An ECDC expert opinion concludes that there is clear evidence supporting the use of neuraminidase inhibitors in the treatment and prevention of influenza. Moreover, the current recommendations in European countries on the use of the neuraminidase inhibitors oseltamivir and zanamivir are appropriate and should be applied by prescribing physicians.
Seasonal influenza vaccination in Europe – Vaccination recommendations and coverage rates for 2013-14 and 2014-15
Overview of vaccination recommendations and coverage rates in the EU Member States for the 2013–14 and 2014–15 influenza seasons.
Recommendations on antivirals in European countries are appropriate, but remain underutilised in practice
Current recommendations in EU countries to use neuraminidase inhibitors (antivirals) for patients with severe influenza are supported by the available evidence, concludes a new expert opinion report from ECDC which is now open for public consultation.
New and updated evaluations of neuraminidase inhibitors for preventing and treating influenza published
This evaluated patients admitted to hospital with laboratory-confirmed or clinically diagnosed influenza A H1N1pdm09 virus infection.